Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects

Clinical Research in Cardiology Supplements

Volumn 10, Issue 1, 2015, Pages 21-25

  Schmitz, Gerd ^a   Orsó, Evelyn ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Biomarker; Cardiovascular risk; Lipoprotein(a); Pathophysiology

Indexed keywords

ANTILIPEMIC AGENT; CHEMOKINE RECEPTOR CXCR3; EPITOPE; ESTROGEN; FIBRIN; FIBRINOGEN; FIBRONECTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSAMINOGLYCAN; KEXIN; LAMININ; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; PLASMIN; PLASMINOGEN; REACTIVE OXYGEN METABOLITE; SUBTILISIN; TETRANECTIN; THROMBOSPONDIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ACUTE PHASE RESPONSE; ANTIANGIOGENIC ACTIVITY; APHERESIS; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; DISEASE COURSE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; GENETIC VARIABILITY; HYPERLIPIDEMIA; IMMUNOASSAY; IMMUNOREACTIVITY; KRINGLE DOMAIN; LIPOPROTEIN APHERESIS SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR REMODELING; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMPLICATION; HUMAN; HYPERLIPOPROTEINEMIAS; ISOLATION AND PURIFICATION; PATIENT SELECTION; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84924986048     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-015-0074-0     Document Type: Article

References (33)

1. Daniels SR, Greer FR, The Committee on Nutrition (2008) Lipid screening and cardiovascular health in childhood. Pediatrics 122:198–208.
2. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA (1998) Association between multiple cardiovascular risk factors and the early development of atherosclerosis. Bogalusa Heart Study. N Engl J Med 338:1650–1656.
3. Orsó E, Ahrens N, Kilalić D, Schmitz G (2009) Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors. Atheroscler Suppl 10:74–78.
4. Lamon-Fava S, Diffenderfer MR, Marcovina SM (2014) Lipoprotein(a) metabolism. Curr Opin Lipidol 25:189–193.
5. Durrington PN, Schofield JD, Siahmansur T, Soran H (2014) Lipoprotein (a): gene genie. Curr Opin Lipidol 25:289–296.
6. Bos S, Yayha R, Roeters van Lennep JE (2014) Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 25:452–460.
7. Berg K (1963) A new serum type system in man – the Lp system. Acta Pathol Microbiol Scand 59:369–382.
8. Utermann G, Weber W (1983) Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 154:357–361.
9. Utermann G (1998) The mysteries of lipoprotein(a). Science (Washington DC) 246:904–910.
10. Rubin J, Kim HJ, Pearson TA, Holleran S, Berglund L, Ramakrishnan R (2008) The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians. Atherosclerosis 201:138–147.
11. Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, Marcovina SM, Giaculli F, Smith MW (2006) Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet 43:917–923.
12. Scanu AM, Edelstein C (1997) Learning about the structure and biology of human lipoprotein a. through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res 38:2193–2206.
13. McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnich GL, Harris WS (2014) Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 8:550–553.
14. Lassman ME, McLaughlin TM, Zhou H, Pan Y, Marcovina SM, Laterza O, Roddy TP (2014) Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 28:1101–1106.
15. Leischik R, Dworrak B (2006) Lipoprotein(a): Bedeutung für das fibrinolytische System und thromboembolische Komplikationen. Herz 31:144–152.
16. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ Jr, Simari RD (2001) Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98:2980–2987.
17. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK (1997) The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 100:2170–2181
18. D’Angelo A, Geroldi D, Hancock MA, Valtulina V, Cornaglia AI, Spencer CA, Emanuele E, Calligaro A, Koschinsky ML, Speziale P, Visai L (2005) The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. Biochim Biophys Acta 1687:1–10.
19. Cho T, Jung Y, Koschinsky ML (2008) Apolipoprotein(a), through its strong lysine-binding site in KIV10, mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem 283:30503–30512.
20. Hoover-Plow J, Hart E, Gong Y, Shchurin A, Schneeman T (2009) A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. Exp Biol Med 234:28–34.
21. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686.
22. Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, Friedrich SO, Kostner GM, Schmitz G (2001) Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor-2 in human monocytes. Blood 97:981–986.
23. Buechler C, Ullrich H, Aslanidis C, Bared SM, Lingenhel A, Ritter M, Schmitz G (2003) Lipoprotein(a) down-regulates lisosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta 1642:25–31.
24. Tsimikas S, Witztum JL (2008) The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19:369–377.
25. Miller YI, Tsimikas S (2013) Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol 24:426–437.
26. Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, Tsimikas S (2013) Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 54:2815–2830.
27. Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, Almazan F, Yang X, Iqbal N, Chowdhury P, Maisel A, Witztum JL, Handel TM, Tsimikas S, Miller YI (2013) MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 54:1877–1883.
28. Blencowe C, Hermetter A, Kostner GM et al (1995) Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem 270:31151–31157.
29. Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, Prasad A, Mahmud E, Miller YI, Dennis EA, Witztum JL, Tsimikas S (2014) Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol 63:1961–1971.
30. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, Group of Clinical Investigators (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6:229–239.
31. Thompson GR, HEART-UK LDL Apheresis Working Group (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198:247–255.
32. Thompson GR (2010) Lipoprotein apheresis. Curr Opin Lipidol 21:487–491.
33. Jacobson TA (2013) Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc 88:1294–1311.